Parkinson's Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1

Area of Science:

• Neuroscience
• Immunology
• Cell Biology

Background:

• Parkinson's disease (PD) involves dopaminergic neuron loss, with current therapies offering only symptomatic relief.
• Neuroprotective agents are lacking for mitigating PD progression.
• Stress-inducible phosphoprotein 1 (STIP1) is a co-chaperone with known neuroprotective roles in other neurological models.

Purpose of the Study:

• To investigate STIP1 as a potential neuroprotective factor in Parkinson's disease.
• To identify if STIP1 is a target of PD-specific autoantibodies.
• To explore the role of autoimmune mechanisms in PD pathogenesis.

Main Methods:

• Utilized human induced pluripotent stem cell-derived dopaminergic neurons to test STIP1's neuroprotective effects.
• Conducted a case-control study comparing STIP1 autoantibody levels in PD patients and healthy controls.
• Employed an overlapping peptide library to map PD-specific B cell epitopes on STIP1.

Main Results:

• STIP1 demonstrated neuroprotective effects against staurosporine-induced toxicity in human dopaminergic neurons.
• Higher levels of STIP1 autoantibodies were observed in PD patients (20%) compared to healthy controls (10%).
• Four PD-specific B cell epitopes within STIP1, crucial for its function, were identified.

Conclusions:

• STIP1 shows promise as an endogenous neuroprotective agent for Parkinson's disease.
• Autoimmune responses targeting STIP1 may contribute to PD pathogenesis in a subset of patients.
• STIP1 autoantibodies could serve as potential biomarkers for PD.